

Q2 2023 *results*



“We delivered another solid quarter of growth and are excited by the momentum of our R&D pipeline, with a strong flow of positive readouts and regulatory achievements that match our best-in-class ambitions.”

Paul Hudson

Chief Executive Officer, Sanofi

Q2 2023 company sales

€9,965m (+3.3% at constant exchange rates, -1.5% on a reported basis)

Q2 2023 business earnings per share

€1.74 (+8.1% at constant exchange rates, +0.6% on a reported basis)

Sales by global business unit



Specialty Care

€4,403m



Vaccines

€1,223m



General Medicines

€3,114m



Consumer Healthcare

€1,225m

sanofi

Q2 2023 *results*

Sales by geography

US
€3,919m

Europe
€2,458m

Rest of the World
€3,588m

Key R&D milestones



Respiratory syncytial virus (RSV):

US FDA approves our RSV prevention for newborns and infants.



Chronic obstructive pulmonary disease (COPD):

Positive phase 3 data for one of our innovative biologics.



Atopic dermatitis:

Positive topline phase 2b data of novel investigational anti-OX40-ligand monoclonal antibody.



Multiple sclerosis:

Positive phase 2b data for our novel anti-CD40L antibody.

For further information on Q2 2023 results and definitions of financial indicators, please refer to the press release issued on July 28, 2023 at: www.sanofi.com/en/investors

sanofi